Trials / Completed
CompletedNCT02321241
Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD
A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 236 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the TITAN study is to describe the clinical practices of a cohort of patients with wAMD refractory to ranibizumab (persistence of intra-retinal and/or subretinal fluid) who switch to aflibercept after less than 12 months of ranibizumab treatment. The study will be conducted in real-life conditions and will allow describing conditions of use of aflibercept in patients refractory to ranibizumab
Detailed description
The study is both retrsopective and prospective to collect local real life data on patients under routine treatment. The observation periods starts on January 2014. Patients who initiated a treatment by Aflibercept between the 1st of january 2014 and the 31 December 2015 will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aflibercept (EYLEA, BAY-86-5321) | 1. st year: 3 monthly injections followed by 1 injection every two months 2. nd year and following: injection according the visual and anatomical results observed the 1st year |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2017-01-18
- Completion
- 2017-08-18
- First posted
- 2014-12-22
- Last updated
- 2018-07-02
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02321241. Inclusion in this directory is not an endorsement.